Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Aaron Mansfield

Mayo Clinic Minnesota

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (10)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Collaborators (10)

Sanjay Popat

Reader

Institute of Cancer Research

UNITED KINGDOM

View details

Ryan Carr

Mayo Clinic

UNITED STATES

View details

Vivek Subbiah

Professor of Medicine and of Pediatrics

Stanford University

UNITED STATES

View details

Anna Nowak

University of Western Australia

AUSTRALIA

View details

Thorvardur Halfdanarson

Professor of Oncology

Mayo Clinic

UNITED STATES

View details

Anthonie van der Wekken

Scientific Staff

University of Groningen

NETHERLANDS

View details

Daniel W. Bowles

Associate Professor

UNITED STATES

View details

Amit Mahipal

Professor

University Hospitals Seidman Cancer Center

UNITED STATES

View details

Paul Baas

Professor

NETHERLANDS

View details

Gulnaz Stybayeva

Assistant Professor

Mayo Clinic

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aaron Mansfield

Research Interests

Make your next move.

Explore related searches

Articles (10)

Reply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodologic Fragility and Censoring Bias in the 5-Year Update of CheckMate 743”

The role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

EGFR -Mutated Lung Cancer — Letting the Butterfly Out of the Cocoon

Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer

Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab

Collaborators (10)

Sanjay Popat

Ryan Carr

Vivek Subbiah

Anna Nowak

Thorvardur Halfdanarson

Anthonie van der Wekken

Daniel W. Bowles

Amit Mahipal

Paul Baas

Gulnaz Stybayeva

Make your next move.